J Korean Ophthalmol Soc.  2009 Jan;50(1):51-60. 10.3341/jkos.2009.50.1.51.

Short-term Efficacy of Intravitreal Bavacizumab for Polypoidal Choroidal Vasculopathy

Affiliations
  • 1Department of Ophthalmology, Pusan National University Hospital, College of Medicine, Pusan, Korea. bsoum@pusan.ac.kr

Abstract

PURPOSE
To evaluate the short-term effect of intravitreal bevacizumab (Avastin(R)) in polypoidal choroidal vasculopathy.
METHODS
Intravitreal Avastin(R) was injected into 13 eyes of 13 patients with PCV in this retrospective, interventional case study. The follow-up period lasted over 3 months after therapy. Changes in best-corrected visual acuity (BCVA), foveal height determined by optical coherence tomography, and abnormal vasculature in indocyanine green angiography (ICGA) were evaluated.
RESULTS
The mean LogMAR BCVA was 0.82 at baseline, 0.78 at 1 month after treatment, and 0.73 at 3 months after treatment. Visual acuity was stabilized or improved in 13 eyes (100%). The mean foveal height was 288 micrometer at baseline, 231 micrometer (p<0.05) at 1 month after treatment, and 196 micrometer at 3 months after treatment. The polypoidal lesions in ICGA decreased in 4 eyes (31%), although branching vasculature in ICGA was unchanged in 13 eyes (100%).
CONCLUSIONS
Intravitreal injection of Avastin(R) may stabilize visual acuity and reduce macular edema due to decreased retinal pigment epithelial detachment and leaking. However, intravitreal injection had a minimal effect in occlusion of the symptomatic polypoidal lesions and no effect in occlusion of the branching vascular network.

Keyword

Bevacizumab; Polypoidal choroidal vasculopathy

MeSH Terms

Angiography
Antibodies, Monoclonal, Humanized
Choroid
Eye
Follow-Up Studies
Humans
Indocyanine Green
Intravitreal Injections
Macular Edema
Retinal Detachment
Retrospective Studies
Tomography, Optical Coherence
Visual Acuity
Bevacizumab
Antibodies, Monoclonal, Humanized
Indocyanine Green
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr